Tag: Next-gen senolytics

I think the idea of treating aging as a disease that’s treatable and preventable in some ways is a really necessary focus. The OP works with some of the world’s top researchers using HBOT as part of that process to increase oxygen in the blood and open new pathways in the brain to address cognitive decline and increase HealthSpan (vs. just lifespan). Pretty cool stuff!

HBOT in longevity research stands for “hyperbaric oxygen therapy.” It has been the subject of research for its potential effects on healthy aging. Several studies have shown that HBOT can target aging hallmarks, including telomere shortening and senescent cell accumulation, at the cellular level. For example, a prospective trial found that HBOT can significantly modulate the pathophysiology of skin aging in a healthy aging population, indicating effects such as angiogenesis and senescent cell clearance. Additionally, research has demonstrated that HBOT may induce significant senolytic effects, including increasing telomere length and decreasing senescent cell accumulation in aging adults. The potential of HBOT in healthy aging and its implications for longevity are still being explored, and further research is needed to fully understand its effects and potential applications.

2- Are they also looking into HBOT as a treatment for erectile dysfunction?

Definitely! Dr. Shai Efrati has been doing research around that and had a study published in the Journal of Sexual Medicine. Dr. Efrati and his team found that 80% of men “reported improved erections” after HBOT therapy: https://www.nature.com/articles/s41443-018-0023-9

3- I think cellular reprogramming seems to be one of the most promising approaches https://www.lifespan.io/topic/yamanaka-factors/

4-Next-gen senolytics (eg, Rubedo, Oisin, Deciduous).

Cellular rejuvenation aka partial reprogramming (as someone else already said) but not just by Yamanaka (OSKM) factors or cocktail variants but also by other novel Yamanaka-factor alternatives.

Stem cell secretions.

Treatments for aging extra-cellular matrix (ECM).

5- Rapamycin is the most promising short term.

I see a lot of people saying reprogramming, and I think the idea is promising but as someone who worked on reprogramming cells in vitro I can tell you that any proof of concepts in vivo large animal models is far aways.

6- Blood focused therapies ( dilution, plasma refactoring, e5, exosomes) perhaps look at yuvan research.

7- I think plasmapheresis is a technology most likely to be proven beneficial in the near term and also a technology that can be scaled and offered for reasonable prices.

8- Bioelectricity, if we succeed in interpreting the code of electrical signals By which cells communicate , we can control any tissue growth and development including organs regeneration

9- Gene therapy and reprogramming will blow the lid off the maximum lifespan. Turning longevity genes on/expressing proteins that repair cellular damage and reversing epigenetic changes that occur with aging.

10- I don’t think anything currently being researched (that we know of) has the potential to take us to immortality. That’ll likely end up requiring some pretty sophisticated nanotechnology. However, the important part isn’t getting to immortality, but getting to LEV. In that respect, I’d say senolytics and stem cell treatments are both looking pretty promising. (And can likely achieve more in combination than on their own.)

11- Spiroligomers to remove glucosepane from the ECM.

12- Yuvan Research. Look up the recent paper they have with Steve Horvath on porcine plasma fractions.

13- This OP thinks most of the therapies being researched will end up having insignificant effects. The only thing that looks promising to me is new tissue grown from injected stem cells or outright organ replacement. Nothing else will address DNA damage, which results in gene loss, disregulation of gene expression, and loss of suppression of transposable elements.

14- A couple that haven’t been mentioned:

Cancer:

• The killer T-cells that target MR-1 and seem to be able to find and kill all common cancer types.

• Also Maia Biotech’s THIO (“WILT 2.0”)

Mitochondria: Mitochondrial infusion that lasts or the allotopic expression of the remaining proteins SENS is working on.

15- Look for first updates coming from altos labs.

Altos Labs is a biotechnology research company focused on unraveling the deep biology of cell rejuvenation to reverse disease and develop life extension therapies that can halt or reverse the human aging process. The company’s goal is to increase the “healthspan” of humans, with longevity extension being an “accidental consequence” of their work. Altos Labs is dedicated to restoring cell health and resilience through cell rejuvenation to reverse disease, injury, and disabilities that can occur throughout life. The company is working on specialized cell therapies based on induced pluripotent stem cells to achieve these objectives. Altos Labs is known for its atypical focus on basic research without immediate prospects of a commercially viable product, and it has attracted significant investment, including a $3 billion funding round in January 2022. The company’s research is based on the fundamental biology of cell rejuvenation, aiming to understand and harness the ability of cells to resist stressors that give rise to disease, particularly in the context of aging.

16– not so much a “therapy” but I think research into growing human organs may be very promising long term. Being able to get organ transplants made from your own cells means zero rejection issues and no limitations of supply for transplants. Near term drugs like rampamycin show good potential for slowing the aging process and are in human trials.

What is biological reprogramming technology?

Biological reprogramming technology involves the process of converting specialized cells into a pluripotent state, which can then be directed to become a different cell type. This technology has significant implications for regenerative medicine, disease modeling, and drug discovery. It is based on the concept that a cell’s identity is defined by the gene regulatory networks that are active in the cell, and these networks can be controlled by transcription factors. Reprogramming can be achieved through various methods, including the introduction of exogenous factors such as transcription factors. The process of reprogramming involves the erasure and remodeling of epigenetic marks, such as DNA methylation, to reset the cell’s epigenetic memory, allowing it to be directed to different cell fates. This technology has the potential to create new cells for regenerative medicine and to provide insights into the fundamental basis of cell identity and disease.